Improved Quality of Life in ADHD Patients Treated with OROS® MPH
Author Information
Author(s): Berek Michael, Kordon Andreas, Hargarter Ludger, Mattejat Fritz, Slawik Lara, Rettig Klaus, Schäuble Barbara
Hypothesis
Is treatment response different between children and adolescents with ADHD treated with OROS® MPH?
Conclusion
Treatment with OROS MPH for 12 weeks improved symptoms, functioning, and health-related quality of life in children and adolescents with ADHD.
Supporting Evidence
- Significant improvements in ADHD symptoms were observed from baseline to study end.
- Adolescents had a lower health-related quality of life at baseline but improved to comparable levels with children by study end.
- OROS MPH was generally safe and well tolerated with no serious adverse events reported.
Takeaway
Kids and teens with ADHD who took a special medicine called OROS MPH felt better and did better in life after 12 weeks.
Methodology
This study pooled data from two multicenter, prospective, open-label studies assessing ADHD patients treated with OROS MPH over 12 weeks.
Potential Biases
Patient motivation for participation could have been influenced by previous treatment experiences.
Limitations
The studies were open-label and single-arm with no control group, which may introduce bias.
Participant Demographics
The study included 583 children (mean age 9.8 years) and 239 adolescents (mean age 14.4 years), with 85% being male.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website